{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=12", "query": { "intervention": "IV Abraxane", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 1429, "total_pages": 143, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Abraxane&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:26:45.789Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00653939", "title": "A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "Fosbretabulin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mateon Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2008-03", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2015-02-09", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 15, "location_summary": "Campbell, California • Fountain Valley, California • Los Angeles, California + 12 more", "locations": [ { "city": "Campbell", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00653939" }, { "nct_id": "NCT05954312", "title": "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "VVD-130037", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vividion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 290, "start_date": "2023-07-28", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 8, "location_summary": "Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05954312" }, { "nct_id": "NCT07173751", "title": "ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Nab-paclitaxel/Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 558, "start_date": "2025-10-30", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-30", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 71, "location_summary": "Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07173751" }, { "nct_id": "NCT00618826", "title": "A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2006-11", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2017-04-14", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00618826" }, { "nct_id": "NCT02319889", "title": "Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stage I Non-Small Cell Lung Cancer", "Stage II Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiotherapy", "type": "RADIATION" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2016-02-02", "completion_date": "2017-01-19", "has_results": false, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319889" }, { "nct_id": "NCT00499252", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Carcinoma", "Primary Peritoneal Carcinoma", "Recurrent Ovarian Carcinoma" ], "interventions": [ { "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 51, "start_date": "2007-06", "completion_date": null, "has_results": true, "last_update_posted_date": "2018-01-11", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 20, "location_summary": "Aurora, Colorado • New Britain, Connecticut • Lewes, Delaware + 15 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "New Britain", "state": "Connecticut" }, { "city": "Lewes", "state": "Delaware" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Elkton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499252" }, { "nct_id": "NCT02726997", "title": "Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 18, "start_date": "2016-07-06", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02726997" }, { "nct_id": "NCT00300885", "title": "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel", "type": "DRUG" }, { "name": "Carboplatin plus Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 926, "start_date": "2006-02", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300885" }, { "nct_id": "NCT07213804", "title": "A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms", "Fallopian Tube Neoplasms", "Peritoneal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Sofetabart Mipitecan", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin (PLD)", "type": "DRUG" }, { "name": "MIRV", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1630, "start_date": "2025-10-22", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 85, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213804" }, { "nct_id": "NCT00607438", "title": "A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)", "type": "DRUG" }, { "name": "Sorafenib (Nexavar)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Veeda Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2007-09", "completion_date": "2009-05", "has_results": false, "last_update_posted_date": "2012-05-11", "last_synced_at": "2026-11-15T12:26:45.789Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00607438" } ] }